This inventor holds 1 USPTO granted patent. Top assignee: Merck Patent Gesellschaft MIT Beschrankter Haftung. Active years: 1998.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 1998
Title: Burkhart Shraven: Innovator in Tumor Therapy
Introduction
Burkhart Shraven is a notable inventor based in Heidelberg, Germany. He has made significant contributions to the field of biomedicine, particularly in the development of innovative therapeutic solutions for cancer treatment.
Latest Patents
Burkhart Shraven holds a patent for bispecific molecules that recognize lymphocyte antigen CD2 and tumor antigens. The patent describes novel and highly effective bispecific antibody fragments that target the lymphocyte CD2 antigen alongside any variable tumor antigen. This invention also introduces two new monoclonal antibodies, AICD2.M1 and AICD2.M2. The combination of these antibodies, with at least one being a bispecific antibody fragment, shows promise for successful applications in tumor therapy and diagnostics.
Career Highlights
Burkhart Shraven is associated with Merck Patent Gesellschaft mit beschränkter Haftung, where he continues to advance his research and development efforts. His work focuses on creating innovative solutions that can significantly impact cancer treatment methodologies.
Collaborations
He has collaborated with notable colleagues, including Wolfgang Strittmatter and Carlota-Silvia Jaggle, contributing to the advancement of their shared research goals.
Conclusion
Burkhart Shraven's innovative work in bispecific antibody fragments represents a significant advancement in tumor therapy, showcasing the potential for improved cancer treatment options.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile